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Abstract
Purpose—This study evaluates the prevalence and factors associated with major depressive
disorder (MDD) in a population of cancer survivors and the impact of co-occurring MDD and
urinary incontinence (UI) on health-related quality of life (HRQOL).
Methods—The prevalence of MDD risk among cancer survivors (breast, prostate, bladder,
colorectal, lung and endometrial/uterine cancers) and those without cancer was estimated using the
Surveillance, Epidemiology and End Results Program-Medicare Health Outcomes Survey (SEER-
MHOS) linked database (n=9,282 with cancer/n=289,744 without cancer). Risk for MDD was
measured using 3 items from the Diagnostic Interview Schedule and HRQOL was measured by
the SF-36. UI was defined as self-reported leakage of urine causing a problem in previous 6
months. Factors associated with MDD were investigated using logistic regression and the impact
of co-occurring MDD and UI on HRQOL scores was determined using linear regression.
Results—The prevalence of MDD risk ranged from 19.2% for prostate-34.1% for lung. Lung
cancer diagnosis was associated with risk of MDD. Being ≥5 years from diagnosis was associated
with decreased risk of MDD (Prevalence Odds Ratio (POR)=0.82, 95% Confidence Interval (95%
CI): 0.71, 0.95). The coexistence of both UI and MDD was associated with a decrease across
HRQOL subscales; including 40-points on role emotional (RE) score.
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Conclusions—Cancer survivors reporting co-occurrence of UI and MDD experienced
significant decrements in HRQOL.
Implications of cancer survivors—Understanding the combined effect of UI and MDD may
help clinicians to better recognize and alleviate their effects on cancer survivors’ HRQOL.
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Introduction
By the year 2030, an estimated 71 million Americans will be 65 years of age and older,
accounting for approximately 20% of the U.S. population [1]. This large-scale population
shift will result in an increase in cancer incidence as more than 60% of new cancers occur in
adults 65 years of age and older [2]. Approximately 13.7 million people in the U.S. are
currently cancer survivors and this number is expected to increase to 18 million by the year
2022, representing a 31% increase in cancer survivors [3, 4]. Increasing age has been
previously associated with more frequent health problems which can result in negative
impacts on health-related quality of life (HRQOL) [5, 6].
There is increasing awareness of the importance of the overall health of cancer survivors,
and in research to identify potential ways to improve the health care of cancer survivors.
Major depressive disorder (MDD) and urinary incontinence (UI) are both prevalent, non-
cancer issues in the elderly and in cancer survivors, but have been understudied among
cancer survivors. The Center for Disease Control (CDC) and population-based studies
estimate that approximately 1 in 10 adults in the U.S. are currently experiencing major
depression [7]. In addition, the lifetime prevalence of depression is estimated to be 16% in
the general population [8] and is estimated to be even higher in elderly populations, possibly
up to 30% [9]. The rate of MDD is particularly high in those recently diagnosed or being
treated for cancer, with a prevalence ranging from 10% to 25.5%[10]. MDD is a key cause
of disability [11] and has been associated with higher mortality and a higher number of
comorbid conditions [9] among the elderly.
Urinary symptoms are also highly prevalent in the general population, with estimates of
about 17% among men and 38% among women who are above the age of 60 years [12–14].
It has been shown that UI impacts many facets of an individual’s life, including social,
physical, psychological, work productivity and sexual health [15–19]. In addition, urinary
symptoms are associated with certain cancers (for example: bladder, prostate, gynecological
cancers) as well as a side effect of cancer treatments [20–23]. Previous research found that
reporting UI symptoms was independently associated with decreased HRQOL scores in a
population of older Americans across cancer diagnoses [24]. UI is a potentially treatable and
reversible condition; in fact, multiple treatment options exist [25, 26]. For cancer survivors,
who experienced persistent UI symptoms after a prostatectomy or hysterectomy, some
surgical treatments have been effective in improving their symptoms [26–28].
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The link between UI and depression has been described, and the co-occurrence of these two
conditions has been demonstrated to have an additive impact on decrements of HRQOL, in
the general population [29]. However, there has been very little, if any, research
investigating the co-occurrence of MDD and urinary incontinence and the association with
HRQOL among cancer survivors. To help better understand the issues of MDD and urinary
incontinence in cancer survivors, this study aims to evaluate the prevalence of MDD among
older Americans with and without cancer; to determine factors associated with MDD such as
cancer diagnoses (bladder, breast, colorectal, endometrial/uterine, prostate or lung),
demographics, comorbidities, and urinary incontinence symptoms; and to investigate the
combined impact of UI and MDD on HRQOL.
Methods
SEER-MHOS data linkage
This study utilizes the population-based SEER-MHOS database, which links the
Surveillance, Epidemiology and End Results [SEER] program of cancer registries with the
Medicare Health Outcomes Survey [MHOS] to provide detailed information about Medicare
beneficiaries who have been diagnosed with cancer. Extensive details of the SEER-MHOS
data linkage have been published previously [30]. The National Cancer Institute’s SEER
program collects and publishes cancer incidence and survival data from population-based
cancer registries for approximately 28% of the U.S. population [31]. Additionally, SEER
collects demographic, tumor characteristic and selected cancer care data for individuals. The
MHOS, which includes self-reported information on socioeconomic, demographic, co-
morbidity, health and functional status, is given to randomly selected Medicare beneficiaries
from each managed care plan under contract with the Centers for Medicare & Medicaid
Services (CMS) each year. These selected Medicare beneficiaries are given a baseline
survey, and if they are still in the same managed care plan two years later they also receive a
follow-up survey.
IRB exemption was obtained from University of North Carolina at Chapel Hill.
Cohort and participant selection
This cross-sectional analysis draws from the baseline and follow-up data from five SEER-
MHOS cohorts (2001 and 2003, 2002 and 2004, 2003 and 2005, 2004 and 2006, 2005 and
2007). These cohorts were selected as these survey years include measures of both UI and
the depressive symptom questions used in the MDD algorithm. For participants diagnosed
with cancer and who have completed two or more SEER-MHOS surveys, the responses to
the first MHOS survey after the most recent cancer diagnoses were used. For those without
cancer diagnoses, the first survey was used. If the respondent had missing data on any of the
questions used to determine MDD or UI then the follow-up survey was used. Study
participants were excluded for the following reasons: (1) if missing data on MDD or UI
(n=635 for those with cancer diagnosis, n=16,321 for those without a cancer diagnosis); (2)
men with breast cancer diagnosis (n=7) which had too small of a sample size to produce
stable estimates, and (3) participants under the age of 65 years (n=209 for those with cancer
diagnosis, n=20,833 for those without a cancer diagnosis).
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The final sample sizes included in this analysis for 6 different cancer types were as follows:
(1) prostate (n=3,133), (2) female breast (n=2,649), (3) colorectal (n=1,645), (4) bladder
(n=710), (5) lung (n=607) and (6) endometrial and uterine (n=538). 289,744 individuals who
had never been diagnosed with cancer were selected.
SEER-MHOS Measures
In our study, MHOS administered the 3 questions described above from the Diagnostic
Interview Schedule (DIS). Being at “risk of major depressive disorder” (MDD) was defined
using an algorithm by Rost et al., 1993[32]. The algorithm includes two methods in which to
screen positive for MDD. The first is a positive screen for risk of MDD was defined by an
affirmative response to the question ‘In the past year, have you had 2 weeks or more during
which you felt sad, blue or depressed; or when you lost interest or pleasure in things that you
usually cared about or enjoyed? (yes/no)’. The second way to screen positive for risk of
MDD, included an affirmative response to both of the following questions: (1) ‘In the past
year, have you felt depressed or sad much of the time? (yes/no)’; and (2) ‘Have you ever had
2 years or more in your life when you felt depressed or sad most days, even if you felt okay
sometimes? (yes/no)’ in addition to responding at least ‘some of the time’ to the question
‘how much of the time during the past 4 weeks have you felt downhearted and blue? (none
of the time/some of the time/most of the time/all of the time’. This last question is a
replacement for a similar question used in the methods proposed by Rost et al., asking how
much of the time in the past week the participant felt depressed [32].
No information is available on the sensitivity and specificity of these 3 items in a Medicare
population. However, Whooley and colleagues (1997) examined the sensitivity and
specificity of a two-item self-report depression screener from the DIS (“During the past
month, have you often been bothered by feeling down, depressed, or hopeless?” and (2)
“During the past month, have you often been bothered by little interest or pleasure in doing
things?”) in an older study population with an average age of 53 [33]. For Whooley’s two-
item depression screener, a sensitivity of 96% (95% CI: 90–99), specificity of 57% (95% CI:
53–62), and area under the ROC curve of .82 (95% CI: .78–.86) were found [33]. Due to the
similarities in the study populations and the questions administered, it is likely that the
sensitivity and specificity of the 3 DIS items in our Medicare population would be
comparable. The gold standard for identifying those at risk of MDD would be a diagnosis by
a trained physician, which would be immensely difficult to obtain for a sample size as large
as the one utilized here.
UI was defined by an affirmative to the following question: ‘Many people experience
problems with urinary incontinence, the leakage of urine. In the previous six months, have
you accidentally leaked urine? (yes/no)’ in conjunction with indicating that the urine leakage
was either ‘a big problem’ or a ‘small problem’ via the question ‘How much of a problem, if
any, was the urine leakage to you?’ (a big problem/a small problem/not a problem).
HRQOL scores were assessed by the Short-Form 36 (SF-36, version 1) and, subsequently
the Veterans Rand-12 (VR-12). The MHOS switched from the SF-36 to the VR-12 in 2006,
thus affecting the surveys from the last two cohorts included in this analysis. SF-36 and
VR-12 Physical Component Summary (PCS) scores have been linked using a published
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algorithm [34]. The PCS T-score metric was normed, with the average in the U.S.
population being 50 and a standard deviation of 10 [35]. Higher scores reflect better
HRQOL. All available physical subscales were used, including bodily pain (BP), role-
physical (RP), physical functioning (PF) and general health (GH) [36]. The mental subscales
utilized (social functioning (SF), role-emotional (RE) and vitality (VT)) did not include the
Mental Component Summary (MCS) or mental health (MH) subscale as both scales relied
on the one of the questions used to screen for risk of MDD [36]. The subscales were defined
by items that were transformed on a 0–100 scale. The subscales, unlike PCS, are not normed
to the U.S. population average.
Key variables investigated in this analysis included: cancer diagnosis, age at survey, current
smoking status, race, gender, marital status, education, comorbid conditions, time since
diagnosis, cancer severity and difficulty with activities of daily living (defined as responding
affirmatively to one or more of the following: difficulty getting out of a chair, using a toilet,
walking, dressing, eating, or bathing). Comorbid conditions were defined as a dichotomous
variable (yes/no) and were self-reported on the MHOS survey by participants.
Statistical Analysis
Univariate distributions of demographic and clinical covariates of the study population were
characterized by cancer type (bladder, breast, colorectal, endometrial/uterine, lung, and
prostate) and variables were defined as follows (index/referent): MDD (yes/no), UI (yes/no),
age (65–74, 75–84, ≥85), smoking status (yes/no), race (other/non-Hispanic white), gender
(male/female), marital status (other/married), education (> high school, ≤ high school), high
blood pressure (yes/no), stroke (yes/no), chronic lung disease (including COPD, asthma and
emphysema) (yes/no), gastrointestinal (including Crohn’s disease, ulcerative colitis, and
inflammatory bowel disease) (yes/no), diabetes (yes/no), difficulty completing one or more
activities (getting out of a chair, using the toilet, walking, bathing, dressing, eating) (yes/no),
joint pain (yes/no), any cardiovascular disease (one or more of chronic heart failure,
myocardial infarction, angina or coronary artery disease, or other heart condition) (yes/no),
cancer severity (distant or regional/in situ or localized), and time since cancer diagnosis to
time of survey (defined as: survey within 2 years after diagnosis, survey within 2–5 years
after diagnosis, and survey >5 years after cancer diagnosis). Time since diagnosis
categorizations were selected to approximate active or early post treatment, short-term
survival, and long-term cancer survival periods, respectively. A chi-square was used to test
the difference in the distribution of the categorical demographic and clinical covariates
between each cancer group compared to those without cancer. The variable for time since
diagnosis and cancer severity did not have a clear referent group (as the referent group in
this model is those without cancer) and thus was not tested for significance.
Due to the very large sample size of this study, a minimally important difference (MID)
equal to 1/3 of the standard deviation was used to determine statistical significance for
continuous HRQOL measures (PCS is normed to a standard deviation of 10; for subscales,
the standard deviation of those without cancer was used) [37]. Unless noted, all future
references to statistical significance for HRQOL scales are based on their respective MID.
White et al. Page 5






















Logistic regression models were used to examine demographic and clinical factors
associated with MDD by calculating Prevalence Odds Ratios (PORs) and 95% Confidence
Intervals (95% CIs). The variables in the model included all cancer types and other
demographic and clinical factors used in univariate analyses. Another logistic model was
performed limited to cancer survivors (excluding non-cancer individuals) and included
variables for cancer severity and time since cancer diagnosis. Cancer survivors with
colorectal cancer were chosen as the referent group in this second model due to a similar
prevalence of MDD and UI compared to the no cancer group.
Linear regression models were used to estimate the adjusted means on HRQOL, by cancer
site, combined MDD and UI status, adjusting for relevant covariates listed above for the
logistic regression models. A multiplicative interaction was assessed between MDD and UI
for HRQOL using cross-product terms in the linear regression model. For this analysis,
Medicare beneficiaries were defined based on their joint reporting of MDD and UI by
creating 3 dummy variables for the regression models. This resulted in them being
categorized into four different groups: (1) no MDD, no UI; (2) no MDD, UI; (3) MDD, no
UI; and, (4) MDD, UI.
All statistical analysis was completed using SAS 9.3 (Cary, NC).
Results
The distributions of demographic and clinical covariates by cancer type are shown in Table
I. The mean (SD) of PCS in the no cancer population was 39.8 (12.0). The mean score for
many HRQOL scales (PCS, BP, PF, GH, SF, RE and VT) for those diagnosed with lung
cancer was significantly lower than the mean HRQOL score for participants without cancer.
The prevalence of MDD risk among cancer patients ranged from 19.2% in prostate cancer
patients to 34.1% in lung cancer; compared to a prevalence of 20.5% in the no cancer
population. Reporting UI was more common across all cancer types than in the no cancer
group (27.1%) but was particularly high among older Americans with a history of
endometrial/uterine, breast and prostate cancers. In general, the percentage of the no cancer
group suffering from comorbid health conditions tended to be lower than the proportions
among cancer survivors. This may be due, in part, to a higher percentage of individuals of an
older age at the time of survey completion in the cancer group compared to those with no
cancer.
The prevalence of co-occurring UI and MDD risk was highest in those with lung cancer
(14.2%) and endometrial/uterine cancer (12.0%) whereas among those without cancer the
prevalence was 8.6%. The prevalence ranged from 9.2% to 10.8% in all other cancer types.
Factors associated with MDD risk among Medicare beneficiaries with and without cancer
are presented in Table II. Being diagnosed with lung cancer (POR= 1.66, 95% CI: 1.37,
2.01) was associated with the largest increase in odds of risk for MDD across cancer types;
whereas being diagnosed with other cancer diagnoses (breast, colorectal, endometrial/uterine
and prostate) was not associated with elevated MDD risk. Another significant factor
associated with MDD was having difficulty completing daily activities (POR= 2.55, 95%
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CI: 2.50, 2.61). UI was in particular significantly associated with MDD (POR=1.68, 95%CI:
1.63, 1.70), as was being a current smoker (POR= 1.40, 95% CI: 1.35, 1.44). Other variables
with significant POR above 1.2 included being not married, having less education, stroke,
chronic lung disease, gastrointestinal problems, joint pain and cardiovascular disease.
The estimates for factors associated with MDD risk among only the cancer survivors and
when taking into account time since diagnosis and cancer severity are similar in magnitude
to the results presented in Table II. When fitting the same model only among cancer
patients, a slight decrease in odds of MDD (Table III; POR=0.83, 95%CI 0.72, 0.97) was
observed for cancer survivors who were more than 5 years from diagnosis relative to those
less than 2 years from diagnosis. Cancer severity was not significantly related with MDD
risk.
Results from linear regression of co-occurrence of MDD and UI and cancer types associated
with PCS and physical HRQOL subscales (BP, RP, PF and GH) adjusted for demographic
factors and comorbid conditions are presented in Table IVa. Decrements in PCS and
physical subscales associated with UI, MDD and coexisting UI and MDD are illustrated in
Figure 1. The estimate for the intercept in this model represents the adjusted mean PCS or
physical subdomain score for the non-cancer group without any comorbid conditions. A
statistical interaction (p <0.001) was observed between UI and MDD with PCS, BP, RP and
PF, and therefore the results are presented by the combined prevalence of these two
conditions. In this analysis, the co-occurrence of MDD and UI was also associated with an
almost 3-point decrease in PCS (adjusted mean score= 47.36, 95% CI: 47.22, 47.51), which
was not significant based on the MID criteria. However, the co-occurrence of MDD and UI
was significantly associated with decreased HRQOL as defined by the MID criterion for BP
(adjusted mean score=73.48, 95%CI: 74.12, 74.82), RP (adjusted mean score=68.81,
95%CI: 68.10, 69.52) and GH (adjusted mean score=62.31, 95%CI: 62.00, 62.62). For PCS
and GH, lung cancer diagnosis was also significantly associated with decreased scores.
The results for the co-occurrence of MDD and UI and cancer types associated with mental
HRQOL subscales (SF, RE, and VT) are presented in Table IVb. Decrements in mental
subscales associated with UI, MDD and coexisting UI and MDD are also illustrated in
Figure 1. For the three mental subdomains included in this analysis, the co-occurrence of
MDD and UI was significantly associated with decreased HRQOL scores. This was
especially prominent for RE, with an average decrease of 40 points for those with MDD and
UI (adjusted mean score=55.33, 95%CI: 54.65, 56.02). Similarly for SF scores, the co-
occurrence of both MDD and UI was associated with a large observed decrease in SF
(adjusted mean score=71.5, 95%CI: 71.14, 71.87). Similarly to PCS and GH, Medicare
beneficiaries with lung cancer had the lowest SF (adjusted mean score=88.06, 95%CI:
86.14, 89.98) and VT score across cancer types (adjusted mean score=65.33, 95%CI: 63.85,
66.80).
Discussion
There has been considerable previous research that has demonstrated that UI has been
associated with higher prevalence of depression and anxiety in the general population [15,
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38, 39]. However, this is the first study, to our knowledge, to assess the co-occurrence of
MDD risk and UI in a population of older Americans with and without cancer. The results of
this study have high public health impact potential due to the substantial prevalence of MDD
risk. In this population of Medicare beneficiaries, MDD risk was prevalent, ranging between
20–34% among cancer survivors and older Americans without cancer. This study found that
the co-occurrence of MDD risk and UI had a large negative impact on RE and SF scores, as
well as a similar decrease among other HRQOL scales although to a lesser extent. We did
not observe significant changes in PCS meeting our MID criteria except for a 4-point
decrement among lung cancer participants compared to those without cancer; however, the
decrease observed may not have clinical relevance when considering other MIDs proposed
for PCS in the literature [40, 41].
While high prevalence of MDD risk was observed in this study population, only a history of
a lung cancer diagnosis had a strong association with reporting symptoms associated with
MDD. This could be due to the poor prognosis typical of lung cancer diagnoses, as well as
the fact that approximately half of lung cancer patients were within 2 years of diagnosis with
more severe disease and thus, were likely in active treatment [42]. Reporting MDD was
associated with many demographic and clinical factors, with the strongest factors being UI
and having physical difficulty completing activities. Due to the fact that MDD is often
underdiagnosed, the results of this study highlight particular factors that may be useful in
identifying MDD and improving diagnosis and treatment of it among older Americans with
and without cancer [43]. A longitudinal study among men found that untreated depressive
symptoms at baseline to be associated with an almost 3-fold increased risk of nocturia at
follow-up [44]. Therefore, identification and subsequent treatment of MDD may aid in the
prevention of future UI symptoms. [45]
While cancer severity was not found to be associated with MDD, the results do suggest that
increasing years from time of diagnoses among cancer survivors was associated with
decreased odds of reporting MDD. Prevalence of depression being the highest immediately
after diagnosis and decreasing over time has been previously reported among breast cancer
survivors [46, 47] but was not observed in a New Zealand cohort of cancer survivors [48].
These differences could be due to geographic differences in the study populations or
differing medical and treatment experiences. A population-based study of long-term cancer
survivors did not find an increased risk of MDD compared to the general population [49],
which supports the finding reported here that suggests MDD risk might be more relevant in
the first two years after a diagnosis.
We also found age at time of survey to be inversely associated with risk of MDD, although
this effect was not strong in magnitude. Previous reports investigating the effect of aging on
risk of MDD or depressive symptoms have been inconsistent [50–52]. Although not
established, it has been hypothesized that increased age after a certain threshold may be
associated with a decreased susceptibility to depressive symptoms or anxiety due to
decreased emotional responsiveness [51].
The prevalence of MDD reported in this study is comparable to depression estimates
previously reported among elderly populations [9]. Our method of defining MDD risk was
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based on a previous published algorithm for determining risk MDD based on a similar
questionnaire [32]. A sensitivity analysis defining ‘depressive symptoms’ as an affirmative
response to any one of the three MDD questions increased the prevalence but did not
significantly alter results of conclusions for the predictors of MDD or the associations with
HRQOL scales.
Decrements across multiple HRQOL scales (PCS, GH, SF and VT) were associated with
lung cancer diagnoses. However, for many of the HRQOL subscales the lowest average
adjusted mean score was observed for the coexistence of both MDD and UI; this decrement
was particularly strong for SF and RE. The decrements observed ranged in magnitude from
almost 10 points on the PF to almost 40 on RE; changes this large in magnitude are
considered moderate to large clinically important differences [40]. This suggests that these
two conditions together have a considerable impact on the emotional and social lives of
Medicare beneficiaries, more so than the cancer diagnoses investigated in this analysis.
Improved awareness of the emotional and social impact of these conditions, among other
HRQOL decrements, may promote the advancement of strategies for detection and
treatment of both MDD and UI.
This study is limited by the cross-sectional nature, and thus we cannot draw conclusions
about temporality between MDD, UI and HRQOL. In addition, there were predictors of
MDD or UI that could not be included in this analysis such as history of MDD, treatment of
MDD, cognitive impairment and social contacts [53]. There were also unmeasured risk
factors for UI such as other urological conditions and reproductive history [54, 55] that
could be relevant to prevalent UI and thus, HRQOL scales. In addition, we could not take
into account cancer treatments due to large amounts of missing data which could have
impacted the relationship between MDD, UI and HRQOL scores.
This analysis has many strengths, in particular it benefits from the large sample size and the
extensive information available in the linked SEER-MHOS database and the ability to
compare across cancer types as well as between cancer survivors and those without cancer.
Many previous reports about MDD in cancer survivors have been limited to investigating
the association in one cancer diagnosis type (eg: breast) [56, 57] or have been conducted in
younger populations [58]. We were also able to adjust for relevant covariates, such as
demographics, comorbid conditions and clinical characteristics that are associated with
MDD and HRQOL scales.
As the population of both cancer survivors and the elderly continue to grow in the U.S., it
will be important to identify health concerns that contribute to quality of life. In particular,
this report highlights two conditions, MDD and UI, which are prevalent in elderly
populations and the co-occurrence result in significant decrements in HRQOL. Both MDD
and UI are often underdiagnosed, but treatable conditions [38, 44]. The predictors of MDD
identified in this paper could be useful in screening for these conditions in older Americans
with and without cancer, a population already susceptible for lower HRQOL. By better
understanding the predictors of MDD and the joint impact of MDD and UI among cancer
survivors, survivorship efforts can be focused to address these conditions and improve the
HRQOL of this growing population.
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Decrements in physical and mental HRQOL subscalesa associated with urinary incontinence
(UI), major depressive disorder (MDD) and coexisting MDD and UI among Medicare
beneficiaries, adjusting for demographics and comorbid conditionsb.
aBP= bodily pain; RP= role-physical; PF= physical functioning; GH= general health; SF=
social functioning; RE= role-emotional; VT=vitality
bDemographics and comorbidities adjustment set (index, referent): age at survey (65–74,
75–84, 85+), smoker (yes, no), race (other, white), gender (male, female), marital status
(other, married), education (> high school, ≤ high school), high blood pressure, stroke,
chronic lung disease (includes COPD, emphysema or asthma), gastrointestinal problems
(including Crone’s, ulcerative colitis, or inflammatory bowel disease) diabetes, difficulty
completing one or more activities (getting out of chair, use of toilet, walking, eating,
dressing, bathing), joint pain, cardiovascular disease
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Table II
Logistic regression results for associations with major depressive disorder (MDD) compared to older
Americans without cancer.
Variable POR 95% CI P
Urinary Leakage
UI 1.68 (1.63, 1.70) <.0001
Cancer typea
Bladder 1.21 (1.00, 1.47) 0.05
Breast 1.00 (0.90, 1.12) 0.9
Colorectal 1.06 (0.92, 1.21) 0.4
Endometrial/Uterine 0.99 (0.79, 1.24) 0.9
Lung 1.66 (1.37, 2.01) <.0001
Prostate 1.03 (0.93, 1.14) 0.6
Demographicsb
Age (65–74) 1.19 (1.15, 1.23) <.0001
Age (75–84) 1.03 (0.99, 1.06) <.0001
Current Smoker 1.40 (1.35, 1.44) <.0001
Race (non-white) 1.17 (1.14, 1.20) <.0001
Gender (male) 0.96 (0.94, 0.98) 0.001
Marital Status (not married) 1.47 (1.44, 1.50) <.0001
Education (> high school) 0.70 (0.69, 0.72) <.0001
Comorbid conditionsb
High blood pressure 1.06 (1.04, 1.09) <.0001
Stroke 1.45 (1.40, 1.50) <.0001
Chronic lung disease 1.39 (1.35, 1.42) <.0001
Gastrointestinal problems 1.80 (1.72, 1.87) <.0001
Diabetes 1.14 (1.11, 1.16) <.0001
Joint Pain 1.32 (1.29, 1.35) <.0001
Cardiovascular disease 1.31 (1.29, 1.34) <.0001
Activities of daily living
Difficulty 2.55 (2.50, 2.61) <.0001
a
Noncancer participants are referent for cancer type
b
Demographics and comorbidities adjustment set (index, referent): age at survey (65–74, 75–84, 85+), smoker (yes, no), race (other, white), gender
(male, female), marital status (other, married), education (> high school, ≤ high school), high blood pressure, stroke, chronic lung disease (includes
COPD, emphysema or asthma), gastrointestinal problems (including Crone’s, ulcerative colitis, or inflammatory bowel disease) diabetes, joint
pain, cardiovascular disease, and difficulty completing one or more activities (getting out of chair, use of toilet, walking, eating, dressing, bathing)
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Table III
Logistic regression results for associations with major depressive disorder (MDD) among cancer cases,
controlling for cancer severity and time since diagnosis.
Variable POR 95% CI P
Urinary Leakage
UI 1.62 (1.43, 1.83) <.0001
Cancer typea
Bladder 1.20 (0.92, 1.56) 0.2
Breast 0.95 (0.77, 1.18) 0.7
Colorectal 1.00 (ref) -- --
Endometrial/Uterine 0.98 (0.72, 1.19) 0.9
Lung 1.36 (1.04, 1.77) 0.02
Prostate 0.96 (0.78, 1.19) 0.7
Demographicsb
Age (65–74) 1.35 (1.10, 1.64) 0.001
Age (75–84) 1.13 (0.94, 1.36) 0.7
Current Smoker 1.37 (1.12, 1.67) 0.002
Race (non-white) 1.04 (0.89, 1.21) 0.6
Gender (male) 1.02 (0.82, 1.27) 0.9
Marital Status (not married) 1.54 (1.35, 1.75) <.0001
Education (> high school) 0.68 (0.60, 0.80) <.0001
Comorbid conditionsb
High blood pressure 1.10 (0.97, 1.26) 0.1
Stroke 1.38 (1.15, 1.67) 0.007
Chronic lung disease 1.46 (1.25, 1.71) <.0001
Gastrointestinal problems 1.93 (1.54, 2.42) <.0001
Diabetes 0.96 (0.82, 1.11) 0.5
Joint Pain 1.31 (1.15, 1.49) <.0001
Cardiovascular disease 1.24 (1.09, 1.41) 0.0009
Time from cancer to survey
<2 years 1.00 (ref) -- --
2–5 years 0.86 (0.72, 1.02) 0.08
≥5 years 0.83 (0.72, 0.97) 0.02
Cancer Severity
In situ/Localized 1.00 (ref) -- --
Regional/Distant 1.07 (0.93, 1.22) 0.4
Activities of daily living
Difficulty 2.80 (2.44, 3.20) <.0001
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a
Colorectal cancer patients within 2 years of treatment, with in situ/localized cancer and those in the referent group of all demographic and
comorbid conditions are referent group in model.
b
Demographics and comorbidities adjustment set (index, referent): age at survey (65–74, 75–84, 85+), smoker (yes, no), race (other, white), gender
(male, female), marital status (other, married), education (> high school, ≤ high school), high blood pressure, stroke, chronic lung disease (includes
COPD, emphysema or asthma), gastrointestinal problems (including Crone’s, ulcerative colitis, or inflammatory bowel disease) diabetes, joint
pain, cardiovascular disease, and difficulty completing one or more activities (getting out of chair, use of toilet, walking, eating, dressing, bathing)
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